• Explore /
  • Poster
  • / Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel).

Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel).

Abstract Poster

Authors

null

Nicholas Stong

Bristol Myers Squibb, Princeton, NJ

Nicholas Stong , Ethan Thompson , Amy Xu , Julie Rytlewski , Arnaud Amzallag , Timothy Brandon Campbell , Sundar Jagannath , Nikhil C. Munshi , Julia Piasecki , Debashree Basudhar , Maria Ortiz Estevez , Shari Kaiser , Erin Flynt , Nathan Martin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8035)

DOI

10.1200/JCO.2023.41.16_suppl.8035

Abstract #

8035

Poster Bd #

27

Abstract Disclosures

Similar Posters

First Author: Salomon Manier

First Author: Julia Piasecki

First Author: Cyrille Touzeau

First Author: Malin Hultcrantz